NEWSROOM
McDermott Will & Schulte advises Verified Clinical Trials in recapitalization by WindRose Health Investors
Aug 10, 2026
Read time: 2 min
Global law firm McDermott Will & Schulte represented Verified Clinical Trials (VCT), the global leader in solutions addressing patient safety, compliance, and data integrity from patient enrollment through study completion, as both deal and regulatory counsel in its recapitalization by WindRose Health Investors, a New York-based healthcare private equity firm.
This deal positions VCT to capitalize on the rapidly growing adoption of its solutions, as well as further develop additional data and analytics capabilities to better serve pharmaceutical sponsors, CROs and clinical trial sites.
The team was led by Marshall Jackson and William Hadler with invaluable support from Brandon Sarkauskas, Jake Schindler, Kevin Hall, Sharon Lamb, Amy Pimentel, Deepak Tamasker, Olivia Palmer, Jiayan Chen, Matt Celentano, Niraj Patel, Jeffrey Holdvogt, Michael Wilder, Alfonso de Reyes-Lanfranco, Noah Feldman Greene, Timothy (Ty) Carson, Max Biedermann, Brian Mead, Wondha Cadet, Payton Thornton, Akiva Ungar, and Kelly Holloway.
Read WindRose’s press release here.
Media Contact
